TP71M-0175+017530 TP

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional report with the FDA on 2019-01-29 for TP71M-0175+017530 TP manufactured by Synergeyes, Inc..

Event Text Entries

[134346612] Follow-up with dr. (b)(6) on (b)(6) 2019: patient issue has resolved as of (b)(6) 2019.
Patient Sequence No: 1, Text Type: N, H10


[134346613] On october 4, 2018: dr. (b)(6)'s office called consultation to report that pt. Had corneal abrasions two times (x2). Treated with steroid/antibiotic treatment combo tobradex. Doctor thought first abrasion was due to foreign body (fb). Then second abrasion occured due to central bearing. Original order sent in as regular cornea. Viewing topography sent today (4 october 2018) early pmd (pellucid marginal degeneration). Need to be re-fit. Will speak to pt. Regarding cost/cgh. Patient injury form sent to doctor. On december 10, 2018: patient injury form and two labeled lenses received at customer care/returns dept. Patient injury form stated the following: potential patient injury codes: eye care professional checked off 105- other injury. Patient injury information: checked off yes; the injury occured during the 90 day fitting period. Right eye (od) was uncomfortable, removed lenses mid-day, "feel" decreased comfort, right eye (od). Could not remove lens (b)(6), slept in them overnight. Eyelash appeared to be trapped under the lens. Checked off yes; the patient has pre-existing condition(s) (dry eyes) that may have caused or contributed to the event. Checked off yes; medical treatment was required to resolve the injury. Patient "treatmewnt" information: treatment was (the) therapeutic, tobradex od (right eye) qid (4 times a day) for x2 weeks. D/c (discontinue) contact lens wear. Condition has not resolved as of (b)(6) 2018. Patient to return on (b)(6) 2018 to check va (vision awareness) "ans" assess cornea. Decreased va (vision awareness) od (right eye) will reassess @ next follow-up. On (b)(6) 2018: abrasion improved. On (b)(6) 2018: to (topography) spk (superficial punctate keratitis) od (right eye)- cleared up 2 weeks later. On (b)(6) 2019: follow-up from consultation with doctor's office. Eye care professional confirmed the injury was treated therapeutically and not prophylactically with tobradex qid (four times a day) x 10 days to reduce swelling of secondary edema, no active infection.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3005087645-2019-00002
MDR Report Key8285111
Report SourceHEALTH PROFESSIONAL
Date Received2019-01-29
Date of Report2019-01-04
Date of Event2018-08-18
Date Mfgr Received2018-12-10
Device Manufacturer Date2018-07-24
Date Added to Maude2019-01-29
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS. NORA YORK
Manufacturer Street2232 RUTHERFORD. ROAD
Manufacturer CityCARLSBAD 920088836
Manufacturer CountryUS
Manufacturer Postal920088836
Manufacturer Phone7604449636
Manufacturer G1SYNERGEYES, INC
Manufacturer Street2232 RUTHERFORD ROAD
Manufacturer CityCARLSBAD CA 920088836
Manufacturer CountryUS
Manufacturer Postal Code920088836
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Generic NameDUETTE PROGRESSIVE CN WITH TANGIBLE HYDRA-PEG
Product CodeHQD
Date Received2019-01-29
Returned To Mfg2018-12-10
Model NumberTP71M-0175+017530
Catalog NumberTP
Lot Number082191
OperatorLAY USER/PATIENT
Device AvailabilityR
Device Age6 MO
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerSYNERGEYES, INC.
Manufacturer Address2232 RUTHERFORD CARLSBAD CA 920088836 US 920088836


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2019-01-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.